Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 3 boards, counting each seat separately. Longest: Travere Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Travere Therapeutics Inc. May 19, 202698.5%
-
AnaptysBio Inc. June 17, 202584.2%
-
Travere Therapeutics Inc. May 15, 202597.9%
-
Travere Therapeutics Inc. May 8, 202474.5%
-
Travere Therapeutics Inc. May 17, 202382.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | AnaptysBio Inc. | Option exercise | +1,300 | — | — |
| Sep 15, 2026 | First Tracks Biotherapeutics Inc. | Option exercise | +1,300 | — | — |
| Jun 15, 2026 | First Tracks Biotherapeutics Inc. | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | AnaptysBio Inc. | Option exercise | +6,030 | — | — |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| Sep 15, 2025 | AnaptysBio Inc. | Option exercise | +1,300 | — | — |
| Jun 15, 2025 | AnaptysBio Inc. | Option exercise | +6,030 | — | — |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| Sep 15, 2024 | AnaptysBio Inc. | Option exercise | +1,300 | — | — |
| Jun 15, 2024 | AnaptysBio Inc. | Option exercise | +2,035 | — | — |
| May 8, 2024 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| May 17, 2023 | Travere Therapeutics Inc. | Grant or award | +4,500 | — | — |
Questions about John A. Orwin
What boards is John A. Orwin on?
John A. Orwin sits on the boards of AnaptysBio Inc., First Tracks Biotherapeutics Inc. and Travere Therapeutics Inc.
How long has John A. Orwin served on boards?
Our records show at least 7 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.